
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (18): 2286-2292.DOI: 10.12114/j.issn.1007-9572.2022.0861
Special Issue: 肿瘤最新文章合辑; 消化系统疾病最新文章合辑
• Evidence-based Medicine • Previous Articles Next Articles
Received:2022-10-21
Revised:2023-02-05
Published:2023-06-20
Online:2023-02-27
Contact:
YAO Ping
通讯作者:
姚萍
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0861
| 第一作者 | 发表时间(年) | 癌症类型 | 国家 | 研究起止时间 | FFQ条目(项) | DII成分(个) | 样本量(病例组/对照组,例) | 性别(男/女) | 协变量调整 | NOS评分(分) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 病例组 | 对照组 | ||||||||||
| ABE[ | 2018 | 食管癌 | 日本 | 2001年1月至2005年1月 | 47 | 19 | 433/1 296 | 376/57 | 1 122/174 | ⑥⑦ | 7 |
| SHIVAPPA[ | 2015 | 食管癌 | 伊朗 | NA | 125 | 27 | 47/96 | 18/29 | 38/58 | ①②③⑥⑦⑨⑫ | 7 |
| SHIVAPPA[ | 2015 | 食管癌 | 意大利 | 1992—1997年 | 78 | 31 | 304/743 | 275/29 | 593/150 | ①②③④⑤⑥⑦⑧⑨⑬ | 8 |
| LU[ | 2016 | 食管癌 | 瑞典 | 1994年12月至1997年1月 | 63 | 36 | 594/806 | 488/106 | 667/139 | ①②③④⑥⑦⑨⑩ | 8 |
| SHIVAPPA[ | 2016 | 胃癌 | 意大利 | 1997—2007年 | 78 | 31 | 230/547 | 143/87 | 286/261 | ④⑤⑥⑧⑨ | 8 |
| LEE[ | 2017 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 388/776 | 249/139 | 498/278 | ①④⑥⑦⑨⑩⑪ | 7 |
| SHIVAPPA[ | 2017 | 食管癌 | 爱尔兰 | 2002—2005年 | 101 | 25 | 224/256 | 189/35 | 216/40 | ①②③④⑥⑦⑨⑪⑫⑬ | 7 |
| TANG[ | 2018 | 食管癌 | 中国 | 2008年1月至2009年1月 | 137 | 23 | 359/380 | 260/99 | 269/111 | ①②③④⑥⑦⑧⑩ | 8 |
| VAHID[ | 2018 | 胃癌 | 伊朗 | 2014年12月至2015年5月 | 168 | 31 | 82/95 | 37/45 | 43/52 | ①②③④⑥⑦⑧⑨⑪⑬ | 8 |
| KIM[ | 2020 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 373/752 | 242/131 | 487/265 | ④⑥⑨⑩ | 8 |
| BAREKIAI[ | 2022 | 胃癌 | 阿富汗 | 2019年 | 103 | 29 | 90/180 | 66/24 | 131/49 | ②③④⑥⑨⑩⑪ | 6 |
Table 1 Baseline characteristics and quality evaluation using the Newcastle-Ottawa Scale for included studies
| 第一作者 | 发表时间(年) | 癌症类型 | 国家 | 研究起止时间 | FFQ条目(项) | DII成分(个) | 样本量(病例组/对照组,例) | 性别(男/女) | 协变量调整 | NOS评分(分) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 病例组 | 对照组 | ||||||||||
| ABE[ | 2018 | 食管癌 | 日本 | 2001年1月至2005年1月 | 47 | 19 | 433/1 296 | 376/57 | 1 122/174 | ⑥⑦ | 7 |
| SHIVAPPA[ | 2015 | 食管癌 | 伊朗 | NA | 125 | 27 | 47/96 | 18/29 | 38/58 | ①②③⑥⑦⑨⑫ | 7 |
| SHIVAPPA[ | 2015 | 食管癌 | 意大利 | 1992—1997年 | 78 | 31 | 304/743 | 275/29 | 593/150 | ①②③④⑤⑥⑦⑧⑨⑬ | 8 |
| LU[ | 2016 | 食管癌 | 瑞典 | 1994年12月至1997年1月 | 63 | 36 | 594/806 | 488/106 | 667/139 | ①②③④⑥⑦⑨⑩ | 8 |
| SHIVAPPA[ | 2016 | 胃癌 | 意大利 | 1997—2007年 | 78 | 31 | 230/547 | 143/87 | 286/261 | ④⑤⑥⑧⑨ | 8 |
| LEE[ | 2017 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 388/776 | 249/139 | 498/278 | ①④⑥⑦⑨⑩⑪ | 7 |
| SHIVAPPA[ | 2017 | 食管癌 | 爱尔兰 | 2002—2005年 | 101 | 25 | 224/256 | 189/35 | 216/40 | ①②③④⑥⑦⑨⑪⑫⑬ | 7 |
| TANG[ | 2018 | 食管癌 | 中国 | 2008年1月至2009年1月 | 137 | 23 | 359/380 | 260/99 | 269/111 | ①②③④⑥⑦⑧⑩ | 8 |
| VAHID[ | 2018 | 胃癌 | 伊朗 | 2014年12月至2015年5月 | 168 | 31 | 82/95 | 37/45 | 43/52 | ①②③④⑥⑦⑧⑨⑪⑬ | 8 |
| KIM[ | 2020 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 373/752 | 242/131 | 487/265 | ④⑥⑨⑩ | 8 |
| BAREKIAI[ | 2022 | 胃癌 | 阿富汗 | 2019年 | 103 | 29 | 90/180 | 66/24 | 131/49 | ②③④⑥⑨⑩⑪ | 6 |
| 分组依据 | 研究数量(篇) | 异质性检验 | OR(95%CI) | 组间异质性 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | P值 | I2值(%) | |||
| 地域 | 0.400 | 0 | ||||
| 亚洲 | 7[ | 0.04 | 55 | 1.98(1.55,2.53) | ||
| 欧洲 | 4[ | 0.94 | 0 | 2.31(1.78,3.00) | ||
| 性别 | 0.007 | 86.7 | ||||
| 男 | 3[ | 0.24 | 30 | 1.27(0.89,1.83) | ||
| 女 | 3[ | 0.81 | 0 | 2.61(1.79,3.79) | ||
| 食管癌病理分型 | 0.930 | 0 | ||||
| 鳞癌 | 5[ | 0.004 | 74 | 2.68(1.74,4.13) | ||
| 腺癌 | 2[ | 0.17 | 47 | 2.59(1.44,4.69) | ||
| Hp感染 | 0.280 | 14.2 | ||||
| 阴性 | 3[ | 0.39 | 0 | 1.47(1.08,1.99) | ||
| 阳性 | 3[ | 0.47 | 0 | 1.90(1.33,2.71) | ||
| FFQ方式 | 0.002 | 84.3 | ||||
| 自我管理 | 3[ | 0.62 | 0 | 1.68(1.53,1.85) | ||
| 面试官管理 | 3[ | 0.28 | 22 | 2.95(1.96,4.43) | ||
| 未提及 | 5[ | 0.86 | 0 | 2.41(1.88,3.08) | ||
| DII成分数量 | 0.600 | 0 | ||||
| >30个 | 6[ | 0.16 | 37 | 2.01(1.57,2.57) | ||
| <30个 | 5[ | 0.06 | 56 | 2.25(1.58,3.22) | ||
| 总能量摄入调整 | 0.010 | 84.6 | ||||
| 是 | 8[ | 0.30 | 17 | 2.23(1.85,2.68) | ||
| 否 | 3[ | 0.27 | 25 | 1.70(1.53,1.88) | ||
Table 2 Subgroup analyses results for DII and UGIC risk
| 分组依据 | 研究数量(篇) | 异质性检验 | OR(95%CI) | 组间异质性 | ||
|---|---|---|---|---|---|---|
| P值 | I2值(%) | P值 | I2值(%) | |||
| 地域 | 0.400 | 0 | ||||
| 亚洲 | 7[ | 0.04 | 55 | 1.98(1.55,2.53) | ||
| 欧洲 | 4[ | 0.94 | 0 | 2.31(1.78,3.00) | ||
| 性别 | 0.007 | 86.7 | ||||
| 男 | 3[ | 0.24 | 30 | 1.27(0.89,1.83) | ||
| 女 | 3[ | 0.81 | 0 | 2.61(1.79,3.79) | ||
| 食管癌病理分型 | 0.930 | 0 | ||||
| 鳞癌 | 5[ | 0.004 | 74 | 2.68(1.74,4.13) | ||
| 腺癌 | 2[ | 0.17 | 47 | 2.59(1.44,4.69) | ||
| Hp感染 | 0.280 | 14.2 | ||||
| 阴性 | 3[ | 0.39 | 0 | 1.47(1.08,1.99) | ||
| 阳性 | 3[ | 0.47 | 0 | 1.90(1.33,2.71) | ||
| FFQ方式 | 0.002 | 84.3 | ||||
| 自我管理 | 3[ | 0.62 | 0 | 1.68(1.53,1.85) | ||
| 面试官管理 | 3[ | 0.28 | 22 | 2.95(1.96,4.43) | ||
| 未提及 | 5[ | 0.86 | 0 | 2.41(1.88,3.08) | ||
| DII成分数量 | 0.600 | 0 | ||||
| >30个 | 6[ | 0.16 | 37 | 2.01(1.57,2.57) | ||
| <30个 | 5[ | 0.06 | 56 | 2.25(1.58,3.22) | ||
| 总能量摄入调整 | 0.010 | 84.6 | ||||
| 是 | 8[ | 0.30 | 17 | 2.23(1.85,2.68) | ||
| 否 | 3[ | 0.27 | 25 | 1.70(1.53,1.88) | ||
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [1] | LI Yutong, ZHAO Danting, JIANG Feng, WANG Yanna, LIU Yizong, LIANG Wenjuan, LU Jiahai. Systematic Review and Meta-analysis of the Efficacy and Safety of mRNA and Recombinant Protein Subunit Vaccines Against Respiratory Syncytial Virus [J]. Chinese General Practice, 2026, 29(19): 2744-2752. |
| [2] | ZHANG Wenbo, WANG Junlong, ZHANG Yuping, JIANG Shuai, WANG Huaqi. The Risk of Pre-COPD Populations Progressing to COPD under Different Criteria: a Meta-analysis [J]. Chinese General Practice, 2026, 29(19): 2735-2743. |
| [3] | MIAO Jingjie, ZHANG Jinwen, WU Qianhao, HAN Peipei. Research Advances on the Effects of Intermittent Fasting on Cardiometabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2538-2545. |
| [4] | Chinese Nutrition Society Obesity Prevention and Control Branch. Chinese Guidelines for Behavioral and Lifestyle Interventions for Obesity [J]. Chinese General Practice, 2026, 29(16): 2113-2139. |
| [5] | TIAN Anni, YANG Jing, SUN Jing, WANG Shichun. Effect of Robot-assisted Training on the Recovery of Hand Motor Function in Patients with Different Stages of Stroke: a Meta-analysis [J]. Chinese General Practice, 2026, 29(14): 1911-1920. |
| [6] | ZHAN Li, HENG Zhaoyang, HE Liangyu, ZHAO Jie, CHEN Jie, XING Jinshan. Efficacy and Safety of CAR-T Therapy Targeting the B Cell Maturation Antigen on Relapsed/Refractory Multiple Myeloma in Chinese People: a Meta-analysis [J]. Chinese General Practice, 2026, 29(14): 1921-1930. |
| [7] | QIU Shanjiao, CHEN Zhang, LI Anchun, HE Zhiguang, HUANG Wenjing. Screening and Case Finding for Coeliac Disease: Lessons for Chinese General Practice from the RACGP Guidelines of Preventive Activities [J]. Chinese General Practice, 2026, 29(10): 1246-1249. |
| [8] | WANG Fei, HAN Weiyu, SUN Tao. Moxibustion Combined with Three-step Therapy in the Treatment of Cancer Pain: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(09): 1203-1211. |
| [9] | YIN Tingting, TU Wenjing, BAI Yamei, HUANG Lina, LI Yiting, XU Guihua. Study on Healthy Dietary Recommendation Model for Inflammatory Bowel Disease Patients Based on Multi-objective Planning [J]. Chinese General Practice, 2026, 29(08): 1029-1036. |
| [10] | PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952. |
| [11] | ZHANG Ling, HUANG Shuangying, XU Hui, MEI Huiting, HONG Yongping. Effects of Different Exercise Types on Fall Efficacy in the Elderly: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(06): 741-751. |
| [12] | CHEN Zhixin, ZHANG Li, GUO Xinyue, ZHOU Zhongliang, ZHANG Jianduan, XU Jinhang, RONG Shengzhong, ZHAO Li, TIAN Qiyue, WANG Sufang, TIAN Xiangyang, GONG Shaoqing. Study on Dietary Factors Associated with Obesity Among University Freshmen [J]. Chinese General Practice, 2026, 29(03): 361-372. |
| [13] | ZHAO Xuejiao, LI Juan, LI Yujie, LU Ting, Xian Lihong, YAN Huan. Prevalence Trends and Influencing Factors for Post-stroke Cognitive Impairment in China: a Meta-analysis [J]. Chinese General Practice, 2026, 29(03): 380-392. |
| [14] | SHENG Luguang, LIU Dandan, LIU Weibin, LU Jun, LEI Tao, CHEN Qingguang, LU Hao, XU Bilin. Effects of Short-term Dietary Intervention for Obese Patients with Abnormal Glucose Metabolism [J]. Chinese General Practice, 2026, 29(03): 373-379. |
| [15] | ZHOU Wenchao, LIANG Jiaqi, YAO Shangman, XUE Zhao, LIU Long, GUO Xiangjie. Identification of Shared Loci between Hypertension and Parkinson's Disease [J]. Chinese General Practice, 2026, 29(02): 201-206. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||